Silexion reported new preclinical data showing its RNAi candidate SIL204 inhibited proliferation by 83.5% to 99.7% across 11 human tumor cell lines spanning five cancer types, with activity against KRAS mutations G12D, G12V, G12R, G12C, G13C, G12A, Q61H, and G13D. Most IC50 values fell between 23.4 and 85.3 nM, with additional datapoints including 31.5 nM in the pancreatic KP2 G12R line and 105 nM in the colorectal HCT116 G13D line. The company also logged its first gastric cancer signal (SNU-601, G12D; 89.2% inhibition) and the highest inhibition to date in a lung model (NCIH2009, G12A; 99.7%).
The core update is Silexion’s push to validate SIL204 as a pan-KRAS, KRAS-selective RNAi approach with human cell line data and to align that dataset with an accelerated clinical timeline. Regulatory submissions are planned with Israel’s Ministry of Health in Q4 2025 and in the European Union in Q1 2026, aiming to initiate a Phase 2/3 program in the first half of 2026. The company positions this dataset as complementary to prior in silico specificity work, suggesting selectivity for KRAS over NRAS and HRAS. Silexion remains clinical-stage based on an earlier-generation program that completed a Phase 2a study, though SIL204 itself has not yet been detailed clinically.
Strategically, this reads as an expansion play into the broad KRAS market rather than another allele-specific niche. The inclusion of G12R—a common and historically refractory variant in pancreatic cancer—targets an unmet space left by small-molecule programs focused on G12C and, more recently, G12D. A truly isoform-selective pan-KRAS approach could hedge against the mutation heterogeneity and resistance pathways that have constrained allele-specific agents. The counterweight is delivery: extrahepatic tumor targeting remains the rate-limiting step for systemically delivered RNAi, especially in desmoplastic tumors like the pancreas. Silexion’s choice of initial regulatory geographies and the ambition to move directly toward Phase 2/3 suggest a bid to leverage prior platform experience and create optionality before larger U.S. engagements, while staking out differentiation from small-molecule pan-KRAS programs that face tight therapeutic windows.
For sponsors and CROs, any near-term development will likely take a basket design, stratified by mutation and tumor type, with centralized genotyping that most oncology sites already run but will need harmonized reporting for eligibility and response attribution. Control arm selection and endpoint alignment will vary across pancreas, lung, and colorectal cohorts, increasing operational complexity and necessitating thoughtful region-by-region standard-of-care mapping. Sites will need infrastructure for serial biopsies or liquid biopsy to demonstrate KRAS mRNA knockdown and on-target pharmacodynamics, along with monitoring to exclude off-target NRAS/HRAS effects. Vendors positioned in cfDNA analytics, RNA quantification, and imaging-based response assessment should find a near-term opportunity. For patients, a credible G12R path in the pancreas is the most immediate clinical hook, but translation from in vitro potency to in vivo activity—and tolerability—will determine whether that promise is actionable.
The next proof points to watch are in vivo efficacy in xenograft or PDX models across multiple KRAS variants, disclosure of the delivery modality and route of administration, and GLP toxicology that clarifies repeat-dosing feasibility and immunostimulatory risk. Clarity on whether Silexion will pursue a pan-tumor basket with mutation-defined cohorts versus a focused initial beachhead will signal trial footprint and recruitment timelines. A U.S. IND plan, companion diagnostic stance, and combination strategy with chemotherapy or targeted agents will further shape competitiveness. The risk remains straightforward: strong cell-line inhibition often fails to anticipate tumor delivery, durability, and safety in humans. The 2025–2026 filings will only be credible if backed by robust translational and CMC packages that de-risk those execution gaps.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
